Intervention reduces adverse drug reactions in patients with multimorbidity, suggesting effective management of polypharmacy risks.
Background: In multimorbidity and severe acute critical illness, polypharmacy [ref:1] is mostly unavoidable. There is no prevention tool that considers the full range of risks [ref:2] associated with adverse drug reactions (ADRs), intensified by drug-drug interactions (DDIs), drug-disease [for full text, please go to the a.m. URL]
No takes yet. Share an insight, caveat, or question.
Wolf Ursula (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: